Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia
Journal of Thrombosis and Haemostasis · 2026-08 · 24 (8) · 2789-2800
DOI: 10.1016/j.jtha.2026.04.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-08. Verfasst von Rebecca Tarantino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy. Hauptthemen laut MEDLINE: Hemophilia A, Protein Engineering, Blood Coagulation, Factor X. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, Novo Nordisk A/S.
Abstract (Originalsprache)
BACKGROUND: While replacement therapy in hemophilia (H)A and B (HB) has provided remarkable improvements, the development of neutralizing antibodies remains a significant complication, with rational engineering of bypassing (BP) molecules being a relevant issue. OBJECTIVES: This study developed a human factor (F)X variant containing a FIX-derived chimeric activation peptide (AP) driving FVIII or FIX deficiency bypass. METHODS: Engineered variants were expressed and purified, and activation/activity properties were evaluated through functional assays, also in plasma with inhibitors from patients with HA and HB. RESULTS: After screening a panel of recombinant variants, the most promising were purified for functional characterization. Unlike wild-type FX (FXWT), the BP variants FXBP4b and FXBP4c at physiological concentrations effectively normalized the clotting time in HA and HB plasma. Chromogenic assays confirmed that both variants preserved activation via the extrinsic tenase complex or by Russell viper venom X, while the intrinsic activation pathway was impaired, thus favoring their selective dose-dependent FXIa activation. In thrombin generation assays, FXBP4b-c restored the peak and the endogenous thrombin potential in FX-deficient plasma. Remarkably, the FXBP4b outperformed FXWT in HA and HB plasma and showed a comparable or superior activity in comparison with B-domainless FVIII and FIX. Notably, FXBP4b significantly shortened the clotting time in plasma from patients with high-titer anti-FVIII or anti-FIX inhibitory antibodies, with efficacy levels comparable with those of well-established BP agents. CONCLUSION: These results support FXBP4b as a promising and versatile BP agent able to sustain coagulation across multiple hemophilic contexts including inhibitors presence, while maintaining favorable activation profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
- Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
- Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy. Electronic address: pnm@unife.it.
- Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Pediatrics, Perelman School of M…
- Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy. Electronic address: brnlss@unife.it.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- Novo Nordisk A/S
- University of Ferrara
Zitieren
APA
Tarantino, R., Bunce, M. W., Tonetto, E., Testa, M. F., Castaman, G., Bernardi, F., Pinotti, M., Camire, R. M., & Branchini, A. (2026). Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia. Journal of Thrombosis and Haemostasis, 24(8), 2789-2800. https://doi.org/10.1016/j.jtha.2026.04.027
Vancouver
Tarantino R, Bunce MW, Tonetto E, Testa MF, Castaman G, Bernardi F, et al. Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia. Journal of Thrombosis and Haemostasis. 2026;24(8):2789-2800. doi:10.1016/j.jtha.2026.04.027
BibTeX
@article{Tarantino2026,
author = {Tarantino, Rebecca and Bunce, Matthew W and Tonetto, Elena and Testa, Maria Francesca and Castaman, Giancarlo and Bernardi, Francesco and Pinotti, Mirko and Camire, Rodney M and Branchini, Alessio},
title = {Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {8},
pages = {2789--2800},
doi = {10.1016/j.jtha.2026.04.027}
}
EUVIMED